Shattuck Labs Q2 Loss Widens to $15.2M as R&D Costs Climb; Phase 2b Trial Set for Q3
STTK has more than doubled off its 52-week low of $0.712.
Summary
Shattuck Labs reported a Q2 net loss of $15.15 million, or $0.12 per share, widening from the prior year as R&D spending increased to advance its clinical pipeline. The company ended the quarter with $208.3 million in cash and investments, which it expects to fund operations into 2029. This follows a series of capital raises in June that brought in over $86 million and attracted significant institutional buying. The key new development is the planned initiation of a Phase 2b trial for lead candidate SL-325 in Crohn's disease in Q3 2026, with primary endpoint data expected in the first half of 2028. The wider loss and lack of revenue are typical for a clinical-stage biotech, but the cash runway and upcoming trial start provide a clearer path forward.
At the time of this announcement, STTK was trading at $7.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $645.3M. The 52-week trading range was $0.71 to $8.33. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.